Flagging the various health concerns surrounding the Covid anti-viral drug Molnupiravir, ICMR’s Dr Balram Bhargava said that Merck’s corona...

The full treatment of Molulife (brand name) is expected to cost ₹1,400, RC Juneja, chairman of Mankind Pharma, told ET. The brand is expect...

According to one of the conditions, as post marketing surveillance the companies will have to submit periodic safety update reports to the ...

The recommended dose of molnupiravir is 800 mg twice a day for five days. With companies planning to launch 200 mg capsules, a patient will...

Union health minister Mansukh Mandaviya said 13 companies in India will manufacture the drug approved for restricted use under emergency si...

Molnupiravir is the first COVID-19 drug authorised by the Drugs Controller General of India (DCGI) for the treatment of COVID-19 infection ...

The drug firm said it is able to manufacture the active pharmaceutical ingredient (API) as well as the formulation for Molnupiravir, and ha...

Under the licensing deal, Hetero will be allowed to expand access of Molnupiravir in India and in other low-and middle-income countries, fo...

Drug maker Cipla said it will soon make molnupiravir capsules available at all leading pharmacies and Covid treatment centers across the co...

Torrent Pharmaceuticals on Tuesday said it will launch MSD and Ridgeback's molnupiravir under the brand name Molnutor in India for the trea...

Earlier this year, the Mumbai-based drug major had signed a non-exclusive voluntary licensing agreement with MSD to manufacture and supply ...

The MHRA recommended the use of Covid-19 drug molnupiravir as soon as possible following a positive Covid-19 test and within five days of s...

The risk factors include obesity, older age (>60 years), diabetes mellitus, or heart disease. MHRA recommended the use of Molnupiravir as s...

Natco has conducted Phase III trials of molnupiravir and submitted the trial results to the drug regulator this month. "We have submitted p...

The Indian bulk drugs manufacturer joins Divi's Laboratories Ltd as an API maker for Merck's experimental oral drug. Merck has separately e...

MSD entered into a voluntary licensing agreement with five Indian drug makers including Sun Pharma, Cipla, Dr. Reddy’s, Emcure and Hetero f...

Molnupiravir was originally developed to treat influenza before US-based Merck initiated research to repurpose drug for use against SARS-Co...